Quick Take
Clinical-stage urological treatment company UroGen Pharma (Pending:URGN) has finalized proposed terms for its IPO, aiming to sell 3.46 million shares of common stock at a midpoint price of $13.00 per share.
The company is developing a potentially improved method to deliver bladder cancer and overactive bladder treatments.
While the market is forecasted to grow significantly, the company faces major competition from new generation treatments and will likely need much more funding to commercialize its pipeline.
